Large‐scale meta‐analysis of infection risk with JAK–STAT inhibitors in 29,000 patients
In this large meta‐analysis of 74 randomized controlled trials involving more than 29,000 patients, JAK–STAT inhibitors were associated with an increased risk of influenza, bronchitis and herpes infections, particularly herpes zoster, while an increased risk of serious opportunistic or fungal infections was not observed.
Máté Krebs +10 more
wiley +1 more source
Tofacitinib as a Promising Therapeutic Option for Vitiligo: A Systematic Review. [PDF]
Ahmadkhani M +3 more
europepmc +1 more source
JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions. [PDF]
Wu ZX +10 more
europepmc +1 more source
Efficacy and safety of tofacitinib in ankylosing spondylitis patients: a systematic review and meta-analysis. [PDF]
Shen L, Han K, Bo L, Huang F.
europepmc +1 more source
Differential regulation of SOCS signalling and immunoproteasome pathways by JAK inhibitors and TNF inhibitors in rheumatoid arthritis. [PDF]
Ghannam K +10 more
europepmc +1 more source
Successful Treatment of Localized Scleroderma in Intertriginous Areas with Tofacitinib: A Case Report. [PDF]
Xu D, Qian S, Tang Y, Bao W, Xu J.
europepmc +1 more source
Treatment of Isolated Nail Psoriasis with JAK Inhibitor Tofacitinib: A Case Report. [PDF]
Xie J, Luo W, Wang C, Wu W.
europepmc +1 more source
Effectiveness and Safety Profile of Oral Tofacitinib in Alopecia Areata: An Observational Study from a Tertiary Hospital. [PDF]
Bhat YJ +10 more
europepmc +1 more source
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature. [PDF]
Soldera J +4 more
europepmc +1 more source
Effect of JAK Inhibitors on Fatigue and Sleep Quality in Patients with Rheumatoid Arthritis: A Narrative Review. [PDF]
Kowalska A +5 more
europepmc +1 more source

